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ABSTRACT
Introduction: Assessing the consequences of
chronic spontaneous/idiopathic urticaria (CSU)
requires the evaluation of health-related quality
of life (HRQoL) associated with the severity of
CSU signs and symptoms. It is important to
understand how signs, symptoms, and HRQoL
change over time in CSU. Evidence is lacking on
how closely changes in signs and symptoms of
CSU are related to changes in HRQoL. The
objective of this study was to assess the
correlation between changes in
patient-reported outcome measures (PROMs)
of signs and symptoms, dermatologic quality
of life (QoL), and urticaria-specific QoL.
Methods: Latent growth models (LGMs) were
applied to longitudinal data from three
randomized, Phase 3 clinical trials
investigating the efficacy and safety of
omalizumab in CSU.
Results: A near-perfect association between
changes in signs and symptoms and changes
in dermatologic and urticaria-specific QoLs was
identified in each clinical trial when using
LGMs (correlation coefficient range 0.88–0.92).
Conclusion: Evidence showed that changes in
signs and symptoms are closely related to
changes in HRQoL. However, analyses were
performed on clinical trial results of an
extremely effective treatment; a less effective
treatment with much smaller changes over time
may not show such close correlations. Results
suggest that any of these PROMs may be used to
understand changes in CSU.
Keywords: Correlation; Health-related quality
of life; Latent growth model; Quality of life;
Urticaria
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INTRODUCTION
In chronic spontaneous urticaria (CSU) or
‘‘chronic idiopathic urticaria’’, itchy hives
(wheals), angioedema, or both, occur for 6 or
more weeks [1]. Chronic urticaria is common
[2–4], impacting patients’ health-related quality
of life (HRQoL), their ability to perform daily
tasks, and their mental health [1, 5, 6].
CSU severity is assessed by evaluating signs
[hives (changing daily)] and symptoms (itch).
Patients count and record these using a daily
diary such as the Urticaria Activity Score (UAS).
HRQoL impact is assessed using generic,
dermatologic-specific, or urticaria-specific [7]
patient-reported outcome measures (PROMs).
To gauge CSU treatment efficacy, clinicians
must assess changes in the patient’s condition.
Disease-specific HRQoL measures are more
sensitive than generic ones in evaluating disease
impact or detecting severity change or treatment
response [8] and are more informative about CSU
burden and changes in burden. Each PROM type
provides different disease status information; sign
measures do not provide HRQoL insights.
However, if different PROMs showed similar
patterns over time after changes in disease,
clinicians could make inferences about a patient
based on one of them. It is valuable to assess the
extent to which different PROMs provide similar
information about changes in CSU and its effects
on quality of life (QoL), giving clinicians options
for understanding patient experience.
Signs and symptoms of CSU and HRQoL show
moderate correlation [9]. These correlations were
based on only one time point and so did not assess
the strength of relationships between changes in
signs and symptoms and HRQoL changes after
treatment. To understand this requires
comparison of changes across multiple time
points, in multiple outcome measures
simultaneously. Traditionally, an analyst would
create difference scores of a PROM between two
time points for each patient and examine the
correlation between the difference scores of the
two PROMs. But, data may be ignored between
two distal time points, such as baseline and the
end of a study, and this is a piecewise approach,
looking at changes between, say, baseline and a
second time point, then between second and third
time points, and so on. If change in the patient’s
condition is non-linear, this approach only
captures a portion of this change. Such analyses
may have contributed to finding only moderate
correlations between signs and symptoms of CSU
and HRQoL measures. This approach poorly
reflects the longer term patient experience and
does not provide clinicians with the most accurate
understanding of the effect of treatment.
We rejected traditional comparisons of change
over time for the longitudinal modeling
technique of latent growth modeling (LGM).
LGM calculates individual patient change
trajectories across all time points simultaneously;
this allows comparisons between changes in
outcomes from multiple measures in a single
analysis and can account for non-linear changes
in the patient’s condition. This technique was
used to model cancer patients with anemia [10],
but has rarely been applied to clinical trial data
and has not been used within dermatology.
The objective of this study was to use LGM to
assess the extent to which changes in three PROM
types—CSU signs and symptoms, dermatologic
and urticaria-specific QoL—are related in their
patterns of change. The LGM results were
compared with a traditional piecewise approach.
METHODS
Data
Data were collected from three phase 3 trials of
omalizumab in refractory CSU: ASTERIA I
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(40 weeks [11]), ASTERIA II (28 weeks [12]) and
GLACIAL (40 weeks [13]) (Fig. 1). The patients
in all trials were aged 12–75 years, with CSU
refractory to H1 antihistamines (ASTERIA I,
ASTERIA II) and refractory to H1 and H2
antihistamines with or without leukotriene
receptor antagonists (GLACIAL). Treatment
was administered four-weekly from baseline
until 24 weeks in the 40-week trials (ASTERIA
I, GLACIAL) and until 12 weeks in the 28-week
trial (ASTERIA II). The studies conformed to the
Declaration of Helsinki [14]; all were ethically
approved and all patients gave informed
consent.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Measures
Urticaria Activity Score (UAS) [15–17]
The UAS is a self-completed daily diary
measuring CSU signs (hives) and symptoms
(pruritus). Patients record twice-daily number
of hives using a 0–3 range (0 = no hives; 3 = 12
or more hives in 12 h). Patients also record
twice-daily pruritus severity, using a 0–3 range
(0 = none; 3 = severe). The average daily score
for the combined hives and pruritus scores is
summed across 7 days to create a weekly score
(UAS7) ranging from 0 to 42; higher scores
indicate greater severity. Each trial required a
UAS7 score of at least 16 for inclusion.
The UAS7 was calculated weekly during the
trials. For ASTERIA I and GLACIAL, scores were
reported at baseline; at weeks 4, 8, 12, 16, and
Fig. 1 Chronic spontaneous urticaria study design of included trials. CU-Q2OL Chronic Urticaria Quality of Life
Questionnaire, DLQI Dermatology Life Quality Index, UAS7 Urticaria Activity Score over 7 days
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20 during treatment; and at weeks 24, 28, 32,
36, and 40 after treatment stopped. For ASTERIA
II, the UAS7 was reported at baseline, at weeks 4,
8, and 12 during treatment and at weeks 16, 20,
24, and 28 after treatment stopped.
Dermatology Life Quality Index [18–20]
The Dermatology Life Quality Index (DLQI) is a
10-item self-reported questionnaire with a
1-week recall designed to assess QoL in skin
diseases. It is validated in CSU [19, 20]. Each
item has four response categories, ranging from
‘‘not at all’’ (score = 0) to ‘‘very much’’
(score = 3). Individual item scores are summed
to a total score (range 0–30); higher scores
indicate worse QoL.
For ASTERIA I and GLACIAL, the DLQI was
administered at baseline, at weeks 4 and 12
during treatment and at weeks 24 and 40 after
treatment stopped. For ASTERIA II, the DLQI
was administered at baseline, at weeks 4 and 12
during treatment, and at week 28 after
treatment stopped. The DLQI has been
validated for individuals aged 16 years and
older: the analysis used data from this age
range.
Chronic Urticaria Quality of Life (QoL)
Questionnaire [21]
The Chronic Urticaria QoL Questionnaire
(CU-Q2oL) is a 23-item, self-reported,
urticaria-specific measure evaluating physical,
psychosocial, and practical aspects of QoL. It
has a 2-week recall period and six-dimensions:
pruritus, swelling, impact on life activities, sleep
problems, limits, and looks. Each item has five
response categories ranging from ‘‘never’’ to
‘‘very much’’. The total score ranges from 0 to
100; higher scores indicate worse QoL.
The CU-Q2oL was administered at the same
times as the DLQI in all trials. As the instrument
was developed within populations aged 18 years
and older, the analysis used data from this age
range.
Statistical Analyses
Latent growth models (LGM) were applied to
data from the three trials using information
from every available time point. LGM is a
growth curve analysis based on structural
equation modeling; it models individual
trajectories of change, allowing correlation of
patterns of changes between multiple outcome
measures across multiple time points
simultaneously [22]. Unlike analyses that
compare mean changes among groups of
patients, e.g., analyses of variance, LGMs
examine how the change in one variable
across all time points for a given patient
matches the change in another variable for
that patient. Analyses of mean change are
limited to change between two time points
and cannot correlate changes involving
multiple variables. However, LGMs calculate a
slope of change and its corresponding intercept
for every patient for each variable and correlate
those intercepts and slopes of change. The
intercept is the value of the growth curve
(slope of change) at the first assessment point,
similar to the value of the initial observation for
a patient.
LGMs can be conducted using ‘‘full
information maximum likelihood’’, a method
for handling missing data [23]. An adjustment
of the overall variance–covariance matrix (using
maximum likelihood estimation) is based on
the data from complete cases. LGMs
automatically make use of information on all
study participants, assuming data are missing at
random. In contrast, traditional mean
difference score analysis uses data only from
patients with data at both time points, resulting
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in loss of information and precision, with
potential bias.
The analyses were conducted in Mplus
(version 7.11; Muthe´n and Muthe´n, Los
Angeles, California, USA) separately for each
trial, irrespective of treatment arm: patients’
responses on each PROM were pooled to create
one analytic population per trial. The LGMs
were conducted so that UAS7 scores were
modeled across all time points simultaneously
with DLQI and CU-Q2oL scores, allowing the
intercepts and slopes of change to be correlated
between the PROMs [22]. This allowed a direct
comparison of change in one PROM with
change in another. The correlations indicated
how closely changes in the CSU signs and
symptoms measure are reflected in changes in
the QoL measures. The greater the correlation
between the slopes of change in a pair of
PROMs, the greater the similarity in what
these two measures assessed in terms of change.
For illustration, a traditional piecewise
analytic approach was conducted using UAS7
and DLQI scores from ASTERIA I. Difference
scores, reflecting changes in UAS7 and DLQI
scores, were calculated between pairs of time
points for each PROM. Pearson’s correlations
between each pair of difference scores were
examined. These analyses used Stata (version
13.0; StataCorp, College Station, Texas).
RESULTS
Patients’ characteristics at baseline were similar
across each trial (Table 1), except more patients
had baseline angioedema in GLACIAL versus
ASTERIA II. Figure 2a–c show slopes of change
in UAS7 and DLQI scores for ASTERIA I,
ASTERIA II, and GLACIAL. The mean growth
curves for each trial show a decrease in UAS7
and DLQI scores (CSU improvement) during the
treatment period, through week 24 for ASTERIA
I and GLACIAL, and through week 12 for
ASTERIA II, but there was an increase in scores
(CSU worsening) after treatment
discontinuation in all three trials. This pattern
of change was similar for the UAS7 and the
DLQI, with strong correlations: ASTERIA I
(0.91), ASTERIA II (0.88), and GLACIAL (0.92).
For each standardized unit change in UAS7, the
DLQI score changes by nearly the same
standardized amount.
Table 2 shows the mean difference scores in
ASTERIA I for selected pairs of time points for
UAS7 and DLQI, and the correlations between
each pair of difference scores. Unlike the strong
correlation found using LGM (Fig. 2a),
correlations based on piecewise mean difference
scores were moderate (range 0.48–0.72). To
understand the relationship between changes in
UAS7 and DLQI in this approach requires
examining multiple correlations between pairs of
time points, making it more difficult to
understand how changes in signs and symptoms
of CSU are related to changes in dermatologic
QoL. Such changes depend on the time frame:
comparing segments within the same overall time
period may yield different insights. For example,
from baseline to week 12, the correlation is 0.57
between change in UAS7 and change in DLQI.
However, the correlation is 0.64 between baseline
and week 4 and 0.48 between week 4 and week 12.
Figure 3a–c show the slopes of change in
UAS7 and the CU-Q2oL scores for ASTERIA I,
ASTERIA II, and GLACIAL. As with UAS7 and
DLQI, the growth curves reflect the mean
changes in UAS7 and CU-Q2oL for each trial
and show a decrease in UAS7 and CU-Q2oL
scores (CSU improvement) during treatment.
There was an increase in scores (CSU worsening)
after treatment was discontinued. This pattern
was similar for both the UAS7 and the CU-Q2oL.
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The strong correlations for ASTERIA I (0.90),
ASTERIA II (0.89), and for GLACIAL (0.92)
demonstrate that for each standardized unit
change in UAS7, a patient’s score on the
CU-Q2oL would change by nearly the same
standardized amount.
DISCUSSION
The LGM results showed a near-perfect
association between changes in signs and
symptoms and dermatologic QoL and changes
in urticaria-specific QoL. These results, across
Table 1 Baseline characteristics
Characteristic ASTERIA I (Saini et al. [11])
N5 318*
ASTERIA II (Maurer et al. [12])
N5 322*
GLACIAL (Kaplan et al. [13])
N5 335*
Age (years)
Mean (SD) 41.2 (14.5) 42.5 (13.7) 43.1 (14.1)
Median 41.0 42.0 44.0
Sex (% female) 72.6 75.8 71.9
Duration of disease (years)
Mean (SD) 6.9 (9.1) 6.5 (8.6) 7.4 (9.5)
Median 3.7 3.3 3.6
Previous number of CSU medications taken
Mean (SD) 4.7 (2.8) 4.2 (2.7) 6.0 (2.6)
Median 4.0 4.0 6.0
Previous use of systemic steroids for CSUa
% yes 44.0 43.8 49.3
Presence of angioedemaa
% yes 47.5 40.7 53.1**
Weekly number of diphenhydramine (25-mg) tablets takena
Mean (SD) 7.7 (8.3) 7.3 (7.8) 7.7 (9.1)
Median 6.0 5.0 5.0
UAS7 score
Mean (SD) 31.1 (6.6) 30.7 (6.8) 30.9 (6.6)
DLQI score
Mean (SD) 13.4 (6.6) 12.7 (6.2) 13.6 (6.7)
CU-Q2oL score
Mean (SD) 44.6 (18.7) 46.7 (17.0) 43.9 (17.1)
CSU chronic spontaneous urticaria, SD standard deviation
* Includes patients from all arms
** P\0.05 versus ASTERIA II
a Based on data collected via a patient daily e-Diary
Adv Ther (2016) 33:214–224 219
three trials, provided validation of the findings,
confidence in the results and evidence that in
CSU changes in symptom severity are closely
linked to changes in HRQoL. If improvement
over time is found using the UAS7, it is highly
likely that DLQI and CU-Q2oL scores will also
improve, and vice versa. Consequently
clinicians may choose to administer any of
these PROMs and make inferences about
changes over time in the others. However,
Fig. 2 Chronic spontaneous urticaria latent growth curve
trajectories. Correlations between slopes of change in the
UAS7 and the DLQI for ASTERIA I (a), ASTERIA II (b),
and GLACIAL (c). DLQI Dermatology Life Quality Index,
PRO patient-reported outcome, UAS7 Urticaria Activity
Score over 7 days
Table 2 Piecewise results for ASTERIA I: correlations in mean difference scores from baseline between the UAS7 and the
DLQI
Time point Mean difference (SD) Correlation
UAS7 DLQI
Change from baseline to week 4 -11.2 (12.0) -5.7 (6.9) 0.64
Change from baseline to week 12 -17.2 (12.8) -7.7 (7.0) 0.57
Change from baseline to week 24 -20.6 (11.9) -8.4 (7.2) 0.53
Change from baseline to week 40 -14.6 (13.5) -5.7 (7.3) 0.59
Change from week 4 to week 12 -5.1 (9.6) -1.8 (5.4) 0.48
Change from week 12 to week 24 -2.9 (8.6) -0.7 (5.2) 0.55
Change from week 24 to week 40 6.5 (14.4) 2.6 (8.5) 0.72
DLQI Dermatology Life Quality Index, SD standard deviation; UAS7 Urticaria Activity Score over 7 days
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these PROMs do not measure the same
concepts; if clinicians wish to know something
specific about HRQoL versus signs and
symptoms, then the appropriate PROM should
be used.
Small-to-moderate relationships between the
UAS7 and the DLQI [24] and between the UAS7
and the CU-Q2oL [25] were reported using
simple correlation analyses, also seen in
Table 2. This piecewise approach based
correlations on a single time point or
comparing changes between two time points.
The LGM results go beyond this using
individual patient-level information across all
time points simultaneously. Previous studies
had restricted inferences due to the aggregate
focus of the analyses. The present study uses an
individual patient-level focus: the intercepts
and slopes of change for every patient across
all time points are used for correlations,
providing more accurate, comprehensive
understanding of changes.
The assessment period for the UAS7 (daily
but summed to 1 week) and the recall period for
the CU-Q2oL (2 weeks) are different, yet the
correlations between them were as large as
those between the UAS7 and the DLQI (both
1 week). This suggests patients’ HRQoL
experiences of CSU are consistent and that
different recall periods do not attenuate
relationships among the PROMs.
Physicians have a choice of PROMs to assess
the severity impact of CSU and treatment
response. Clinicians can feel confident in
using whichever measure is available and with
whichever they are more familiar. If an
improvement (or worsening) in signs and
symptoms is found, it is highly likely that an
improvement (or worsening) HRQoL is also
experienced, and vice versa.
These results highlight the level of specificity
and potential temporal ordering of HRQoL
measures in CSU. Patient-reported symptoms are
considered most ‘‘proximal’’ to treatment effects
Fig. 3 Chronic spontaneous urticaria latent growth curve
trajectories: correlations between slopes of change in the
UAS7 and the CU-Q2OL for ASTERIA I (a), ASTERIA
II (b), and GLACIAL (c). CU-Q2OL Chronic Urticaria
Quality of Life Questionnaire, PRO patient-reported
outcome, UAS7 Urticaria Activity Score over 7 days
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and the patient’s experience, while HRQoL is
more ‘‘distal’’ to symptoms and treatment effects
[26]. A disease-specific PROM is likely to be more
proximal to symptoms and treatment effects than
a more general HRQoL PROM [26]. However, in
this study changes in CSU signs and symptoms
(that treatment directly affects) are highly
correlated with changes in the generic or CSU
specific QoL measures; knowing one of these
dimensions yields a very good understanding of
the other two-dimensions of the patients’
experience of change.
One potential concern relates to the utilization
of the DLQI and the CU-Q2oL. Some aspects of the
psychometric properties of the DLQI have been
criticized [27]; however, the DLQI has been
validated for use in CSU [19, 28, 29] and the
minimally important difference determined [20].
The CU-Q2oL is a relatively recent addition to the
study of HRQoL in CSU and is recommended for
assessment of HRQoL by international guidelines
[1]. Validation of any measure is a multi-facetted
process and this analysis provides evidenceof these
measures meeting another aspect of validation—
that they change together very closely.
A second concern is that the analyses were of
trial results of an extremely effective treatment.
The analyses pooled all treatment arms,
including placebo. The treatment is so
effective that even when treatment and
placebo patients were pooled, the treatment
effect more than compensates for the lesser
response of those on placebo. A less effective
treatment that resulted in smaller changes
might not show such close correlations.
CONCLUSION
This analysis of CSU PROMs provides support
for clinicians that the results obtained from one
of the PROMs about a change in a patient’s
condition are highly likely to be indicative of
similar changes in the PROM not administered.
Thus, when using just one of the PROMs,
inferences can be made about change in
disease activity, response to treatment, and
changes in HRQoL.
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